论文部分内容阅读
自体骨髓移植(ABMT)支持下增大剂量化疗,用于乳癌、淋巴瘤和其它恶性肿瘤愈见增多。业已证实,它使预后甚差的转移性乳癌无病生存期延长,高危原发乳癌复发危险性降低。然而,它往往使患者住院时间延长,需巨额开支,故这一高科技项目推广应用受到限制。 1991年10月至1993年4月,Duck大学骨髓移植部进行门诊管理下为期一周7天ABMT治疗乳癌的可疗性研究。110例原发或转移的晚期乳癌,均女性,中位年龄40(范围23～60)岁。其中,84例Ⅳ期用过AFM方案(阿霉素、5-FU、氨甲喋呤);21例腋下淋巴结10个以上转移的Ⅱ或Ⅲa期患者用过
Increased dose chemotherapy supported by autologous bone marrow transplantation (ABMT) has become more common in breast cancer, lymphoma, and other malignancies. It has been confirmed that it prolongs the disease-free survival of metastatic breast cancer with a poor prognosis, and reduces the risk of recurrence of high-risk primary breast cancer. However, it often prolongs the hospitalization of patients and requires huge expenditures, so the promotion and application of this high-tech project is limited. From October 1991 to April 1993, the Department of Bone Marrow Transplantation at Duck University performed a seven-day ABMT treatment for breast cancer under outpatient management. 110 cases of primary or metastatic advanced breast cancer were female, with a median age of 40 (range, 23 to 60) years. Among them, 84 patients with stage IV used AFM regimen (adriamycin, 5-FU, methotrexate); 21 patients with stage II or stage IIIa metastasis with more than 10 axillary lymph nodes were used.